Introducing Holigen, a future leader in large-scale, low-cost and high-quality cannabis production from a GMP compliant facility in the EU.
The development of this facility and related infrastructure will support clinicians by providing high-quality medical cannabis products for those who need them. Holigen is committed to working towards improving access to the range of solutions available to patients.
Holigen is a collective organisation consisting of RPK Biopharma and TCann.
TCann incorporates more than 40 years of experience in both the pharmacy and healthcare sectors with involvement in research, production, cultivation, GMP manufacturing and import/export of medical cannabis.
RPK Biopharma holds a cannabis cultivation licence and the first export licence for cannabis in Portugal.
Collectively, Holigen holds licences for both outdoor and indoor cultivation, including one of the largest outdoor cannabis licences in the developed world (65+ hectares/seven million square feet in Aljustrel, Portugal). This project is a designated Project of National Interest in Portugal with access to Euro 2020 funding.
Combining quality production and accessibility
Holigen is focused on growing high-quality cannabis under conditions that will produce high-yield crops with an additional focus on pharmaceutical-grade active cannabis ingredients.
Holigen is positioned well when it comes to the production of medical cannabis products on a large scale for both local European and Australian markets, and for export internationally
With a planned production capacity of more than 500 tonnes/annum of cannabis, Holigen expects to serve more than 35 countries through export by establishing trade agreements in key countries across Europe, including directly with pharmacies.
Holigen’s ownership structure is currently Maltese DFT Trading Ltd (80.2%) and The Flowr Corporation (FLWR) 19.8%. Flowr is publicly listed on the TSX Venture Exchange in Canada.